Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
PHASE3
This is a randomized, double-blind, multicenter trial,parallel control desi...
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
PHASE3
This is a Phase IIIb, multinational, multicenter, randomized, open-label st...
Status
Completed
Location
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
N/A
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a...
Status
Recruiting
Location
Peking University People's Hospital
Start Date
2015-01-01
Trial ID
NCT06711055
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
PHASE3
This multicenter study in participants with HER2-positive eBC will investig...
Status
Completed
Location
State Inst N.N. Alexandrov Republican Scientific & Practical Centre of Oncology & Medical Radiology